Lower end of the SBF 120 index: Exosens stock retreats 2% following its nuclear rebound
The Bordeaux-based optronic company is posting a sharp decline in mid-afternoon, bucking a Paris market that is slightly oriented upward. The move follows a rebound last week, linked to the supply of neutron detectors for American reactors.
A decline that brings the price below its three moving averages
The Exosens stock is down 2.25% at €56.60, while the SBF 120 is gaining 0.14% and the CAC 40 is up 0.12%. The stock is among the largest declines on the index. It is now below its moving averages, 4.12% below the 20-day MA (€59.03) and 5.75% below the 200-day MA (€60.05), after losing 7.37% over a week.
The support level at €54.15 is less than 5% away from the current price. The RSI at 48 remains neutral: the decline is therefore not accompanied by excessive selling pressure, and the stock is maintaining a one-year gain of 30.26%.
Neutron detectors and October 27 publication on the calendar
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On October 8, Exosens announced that it had supplied neutron detectors to Antares Nuclear and Valar Atomics, whose first two reactors reached criticality as part of the U.S. Department of Energy pilot program. The announcement of these supplies was followed by a 2.5% rebound on October 9, which has since been largely erased. The group had also raised its 2026 targets on September 17, with revenue up approximately 20% and adjusted EBITDA advancing by around 25%. The next milestone is the publication of nine-month results, expected on October 27.
Porté par une dynamique commerciale soutenue, en particulier sur les marchés de la Défense et de la Surveillance, ainsi que par une solide exécution opérationnelle
Risks mentioned
Charge de dépréciation de la marque de 28,2 M€ pesant sur le résultat net publié, en baisse de 45,0 %
Incertitudes persistantes sur la recherche scientifique pesant sur la demande en Sciences de la Vie
Contraction de 60 points de base de la marge brute du segment Détection & Imagerie (mix produits)
Opportunities identified
Attribution par l'US Army du contrat IDIQ BiNOD ouvrant le marché américain de la défense
Plan d'expansion de +40 % des capacités de production d'ici 2027, premiers bénéfices au S2 2026
Acquisition d'Emberion, capteurs infrarouges SWIR à points quantiques
Outlook / guidance
Expected revenue: 530 millions d'euros
Expected EBITDA: 173 millions d'euros
Management commentary: chiffre d'affaires compris entre 520 millions d'euros et 540 millions d'euros ; • EBITDA ajusté compris entre 168 millions d'euros et 178 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
